Humanized Anti-TSLP Antibody BSI-045B for Atopic Dermatitis and Severe Uncontrolled Asthma

Partnering objectives
Seeking a collaborative licensing opportunity with a company that has a strategic interest in the treatment of atopic dermatitis and severe uncontrolled asthma – ex-China global rights

Field: Treatment of asthma and atopic dermatitis, chronic obstructive pulmonary disease (COPD) and cat allergy

Technology and MOA
MOA: TSLP inhibitor, a high-affinity humanized anti-TSLP antibody blocks the interaction of thymic stromal lymphopoietin (TSLP) with TSLP receptor.
TSLP is now widely considered to underlie some of the most prevalent inflammatory allergic disorders, such as the atopic diseases (asthma, atopic dermatitis and atopic rhinitis), chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis and has been annotated as a genetic risk factor for the development of asthma and eosinophilic esophagitis.

Marketing opportunity
Asthma, alone, affects 334 million people worldwide, and up to 10% of asthma patients have severe asthma, which may be uncontrolled despite high doses of standard-of-care asthma controller medicines and can require the use of chronic oral corticosteroids (OCS).

Severe uncontrolled asthma is debilitating and potentially fatal with patients experiencing frequent exacerbations and significant limitations on lung function and quality of life (Amgen News Release).
Global market for target TSLP is estimated to reach $1,608 million USD in 2025

Differentiable treatment with potential to be first/ best in class
Biosion has developed a high-affinity humanized anti-TSLP monoclonal antibody (BSI-045B) with 200 folds higher in vitro efficacy as compared to Tezepelumab, which is expected to be approved for market in late 2020

Indications
• Asthma
• Atopic Dermatitis (Atopic Eczema)
• Cat Allergy
• Chronic Obstructive Pulmonary Disease (COPD)

Data
Key parameters of humanized anti-TSLP monoclonal antibody BSI-045B as compared to Tezepelumab:
• Exhibits superior in vitro bioactivities (over 100-fold better) as compared to Tezepelumab
• Show 4-fold higher target-binding affinity and comparable ligand/receptor blocking activity
• Cell-line development and CMC are on-going and is expected to file IND in Q1 of 2021

Intellectual property
Provisional patent file – pending